SRTA
Research Snapshot
Static fundamentals, valuation context, and investor signals for STRATA CRITICAL MEDICAL, INC. (SRTA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
14.8%
ROIC, -29.7% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 6.4x current ratio
Superinvestors
2
Top: Daniel Loeb (1.0%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 9 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -29.7%.
- Valuation multiples are limited or unavailable.
Annual data: 9 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for SRTA.
Grade F
24
/ 100
Financial Charts
No financial data available for SRTA (annual).
2 superinvestors own SRTA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Daniel Loeb Third Point | 5,000,000 | $21M | 1.00% | 0.0% |
| First Eagle Investment Management First Eagle Investment Management | 2,266,243 | $9M | 0.02% | 0.0% |